Mubadala Investment Company, an Abu Dhabi sovereign investor, acquires KELIX bio, a specialty pharmaceutical business focused on delivering complex generics across emerging markets, to further strengthen the development of the UAE’s life sciences ecosystem.
KELIX bio was launched in November 2020, and has since, acquired manufacturing businesses in India, Egypt, Malta and Morocco successfully commercializing a broad range of both oral and injectable formulations covering diverse therapy areas including diabetes, oncology, cardiology, and the central nervous system.
Dr Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, said: “In line with our role as a responsible investor, today’s acquisition is testament to the role Mubadala continues to play in accelerating the nation’s economic diversification through our portfolio of companies and national champions.
“This partnership marks a key milestone in further advancing Mubadala’s position in the life sciences sector, to deliver important long-term socio-economic returns for our nation including improved healthcare, drug security, job creation and GDP impact.”
Ismail Ali Abdulla, Head of UAE Clusters, at Mubadala’s UAE Investments Platform said: “At Mubadala, we are deeply committed to enhancing the well-being of our communities through strategic investments that address critical health care needs. By amplifying our domestic capabilities in producing essential medications via Kelix bio, our goal is to significantly empower the UAE’s healthcare infrastructure, ensuring wider access to life-saving treatments for all citizens. This investment is a testament to our dedication as a responsible investor, emphasizing our commitment to investing in solutions that address the world’s most pressing challenges.”
